6 completed, 2 recruiting, 1 active not recruiting, 1 terminated. 10 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 6, Recruiting 2, Active not recruiting 1, Terminated 1 |
| Phase 2 | 5 | Completed 3, Active not recruiting 1, Recruiting 1 |
Follow Lymphangiomyoma: new trials by email Literature Review of Lymphangiomyoma trials Research Report on Lymphangiomyoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM) Imatimib Mesylate, Placebo - Lymphangioleiomyomatosis (LAM), Lymphangioleiomyomatosis | Phase 1 | Recruiting | Columbia University | 20 | 2025-10-20 | 2026-01-21 |
| Feasibility of [11C]Acetate-PET in LAM and TSC [11C]acetate - Lymphangioleiomyomatosis, Tuberous Sclerosis Complex | Phase 1 / Phase 2 | Active not recruiting | Brigham and Women's Hospital | 7 | 2021-08-30 | 2026-01-21 |
| Glutamine PET Imaging in LAM Glutamine - Lymphangioleiomyomatosis (LAM) | Phase 1 | Completed | Vanderbilt University Medical Center | 5 | 2019-10-18 | 2021-08-11 |
| LAM Pilot Study With Imatinib Mesylate Imatinib Mesylate 400Mg Capsule, Placebo - Capsule - Lymphangioleiomyomatosis | Phase 1 / Phase 2 | Completed | Medical University of South Carolina | 18 | 2018-01-23 | 2020-06-16 |
| The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1) Saracatinib - Pulmonary Lymphangioleiomyomatosis | Phase 1 | Completed | Tony Eissa | 9 | 2014-08-01 | 2016-11-30 |
| Safety of Simvastatin in LAM and TSC Simvastatin, Sirolimus Oral Product, Everolimus Oral Product - Lymphangioleiomyomatosis, Tuberous Sclerosis Complex | Phase 1 / Phase 2 | Completed | University of Pennsylvania | 10 | 2014-03-01 | 2020-08-25 |
| Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis albuterol inhaler, albuterol nebulizer, PFT - Lymphangioleiomyomatosis | Phase 1 / Phase 2 | Recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 100 | 2013-06-10 | 2026-11-09 |
| Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Bevacizumab, Cetuximab, Laboratory Biomarker Analysis - Advanced Malignant Neoplasm, Castleman Disease | Phase 1 | Terminated | M.D. Anderson Cancer Center | 116 | 2012-10-16 | 2026-11-05 |
| Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis "Sirolimus" and "Hydroxychloroquine" 200 mg, "Sirolimus" and "Hydroxychloroquine" 400 mg - Lymphangioleiomyomatosis | Phase 1 | Completed | Brigham and Women's Hospital | 14 | 2012-09-01 | 2018-10-11 |
| RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM RAD001 - Tuberous Sclerosis, Lymphangioleiomyomatosis | Phase 1 / Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 36 | 2005-08-01 | 2013-09-25 |
Lymphangioleiomyomatosis (10) · Tuberous Sclerosis (3) · Breast Neoplasms (1) · Carcinoma, Transitional Cell (1) · Castleman Disease (1) · Endocrine Gland Neoplasms (1) · Erdheim-Chester Disease (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Mouth Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neoplasms, Mesothelial (1) · Neurofibromatosis 2 (1) · Pharyngeal Neoplasms (1) · Recurrence (1)
Hemic and Lymphatic Diseases (10) · Immune System Diseases (10) · Immunoproliferative Disorders (10) · Lymphatic Diseases (10) · Lymphoproliferative Disorders (10) · Neoplasm, Lymphatic Tissue (10) · Neoplasms by Histologic Type (10) · Neoplasms, Connective and Soft Tissue (10) · Perivascular Epithelioid Cell Neoplasms (10) · Neoplasms (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (4) · Heredodegenerative Disorders, Nervous System (4) · Neoplastic Syndromes, Hereditary (4)
Sirolimus (3) · Everolimus (2) · Imatinib Mesylate (2) · Bevacizumab (1) · Cetuximab (1) · Disulfides (1) · Glutamine (1) · Hydroxychloroquine (1) · Immunoglobulin G (1) · Simvastatin (1) · Valproic Acid (1) · carbon-11 acetate (1) · saracatinib (1) · temsirolimus (1)
Brigham and Women's Hospital (2) · Children's Hospital Medical Center, Cincinnati (1) · Columbia University (1) · M.D. Anderson Cancer Center (1) · Medical University of South Carolina (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Tony Eissa (1) · University of Pennsylvania (1) · Vanderbilt University Medical Center (1)
United States (10)
Frank McCormack, MD (2) · Carmen P Priolo, MD PhD (1) · Christopher Meinberg (1) · Elizabeth P Henske, MD (1) · Jeanine D'Armiento, MD, PhD (1) · Joel Moss, M.D. (1) · Joel Moss, MD, PhD (1) · John J. Bissler, M.D. (1) · Khalid Almoosa, MD (1) · Maryl Kreider, MD, MSCE (1) · Nicola A Hanania, MD (1) · Sarina A Piha-Paul (1) · Timothy S Blackwell, MD (1) · Tony Eissa, MD (1) · Vera P Krymskaya, PhD, MBA (1)
PMID 21482669, PMID 26933802, PMID 28192114, PMID 30144422, PMID 31299246, PMID 37311055, PMID 41389341
1ZIAHL002541-21 (1)